Roles and Mechanisms of Dopamine Receptor Signaling in Catecholamine Excess Induced Endothelial Dysfunctions

Zhen Yang1,2, Yingrui Li2, Mengying Huang2

  • 1Department of Ophthalmology, Affiliated Hospital of North Sichuan Medical College, 637000 Nanchong, Sichuan, China.

Insights

High catecholamine levels cause endothelial dysfunction via dopamine receptors and potassium channels. This mechanism involves signaling pathways, leading to reduced nitric oxide and increased oxidative stress, potentially causing vasoconstriction.

Area of Science:

  • Cardiovascular Biology
  • Endothelial Cell Function
  • Molecular Mechanisms

Background:

  • Endothelial dysfunction is implicated in Takotsubo cardiomyopathy pathogenesis.
  • The precise mechanisms of endothelial dysfunction during catecholamine excess remain unclear.

Purpose of the Study:

  • To elucidate the role of D1/D5 dopamine receptors and small conductance calcium-activated potassium channels (SK1-3) in catecholamine-induced endothelial cell dysfunction.
  • To investigate the signaling pathways involved in these effects.

Main Methods:

  • Human cardiac microvascular endothelial cells treated with 100 μM epinephrine (Epi) to mimic catecholamine excess.
  • Utilized patch clamp, FACS, ELISA, PCR, western blot, and immunostaining.
  • Investigated the effects of D1/D5 receptor blockers and agonists.

Main Results:

  • Epinephrine enhanced SK1-3 channel current (ISK1-3) without altering channel expression, an effect blocked by D1/D5 antagonists.
  • D1/D5 agonists replicated epinephrine's effect, confirming receptor involvement.
  • D1/D5 activation of SK1-3 channels involved PKA, ROS, and NADPH oxidases, leading to hyperpolarization, reduced NO, and increased ROS production.

Conclusions:

  • High catecholamine concentrations activate D1/D5 receptors and SK1-3 channels via NADPH-ROS and PKA signaling.
  • This activation reduces nitric oxide (NO) production and increases reactive oxygen species (ROS), potentially promoting vasoconstriction in states of catecholamine excess.

Related Concept Videos

Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
1.4K